- Home
- KRP vs SYRE Comparison
KRP vs SYRE Comparison
Compare KRP & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRP
- SYRE
- Stock Information
- Founded
- KRP 2013
- SYRE 2013
- Country
- KRP United States
- SYRE United States
- Employees
- KRP N/A
- SYRE N/A
- Industry
- KRP Oil & Gas Production
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- KRP Energy
- SYRE Health Care
- Exchange
- KRP Nasdaq
- SYRE Nasdaq
- Market Cap
- KRP 1.1B
- SYRE 1.1B
- IPO Year
- KRP 2017
- SYRE 2016
- Fundamental
- Price
- KRP $13.34
- SYRE $15.05
- Analyst Decision
- KRP Hold
- SYRE Strong Buy
- Analyst Count
- KRP 5
- SYRE 5
- Target Price
- KRP $17.20
- SYRE $61.25
- AVG Volume (30 Days)
- KRP 433.6K
- SYRE 492.5K
- Earning Date
- KRP 11-06-2025
- SYRE 11-06-2025
- Dividend Yield
- KRP 12.87%
- SYRE N/A
- EPS Growth
- KRP N/A
- SYRE N/A
- EPS
- KRP N/A
- SYRE N/A
- Revenue
- KRP $312,566,668.00
- SYRE N/A
- Revenue This Year
- KRP $9.34
- SYRE N/A
- Revenue Next Year
- KRP $2.80
- SYRE N/A
- P/E Ratio
- KRP N/A
- SYRE N/A
- Revenue Growth
- KRP N/A
- SYRE N/A
- 52 Week Low
- KRP $10.98
- SYRE $10.91
- 52 Week High
- KRP $16.99
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- KRP 39.58
- SYRE 37.57
- Support Level
- KRP $13.34
- SYRE $14.67
- Resistance Level
- KRP $13.85
- SYRE $17.58
- Average True Range (ATR)
- KRP 0.26
- SYRE 0.74
- MACD
- KRP -0.04
- SYRE -0.23
- Stochastic Oscillator
- KRP 25.23
- SYRE 13.21
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.